← Back to all trials
Not Yet Recruiting
NCT07868926
Absorption, Distribution, Metabolism, and Excretion of 14C-VX-407 After a Single Oral Dose
Conditions: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Sex: Male
Ages: 19 Years – 55 Years
Healthy volunteers: Yes
Phase: PHASE1
Enrollment: 8
Sponsor: Vertex Pharmaceuticals Incorporated
Summary
The purpose of the study is to evaluate the pharmacokinetics, safety and tolerability of VX-407 following a single oral dose.
Eligibility Criteria
Key Inclusion Criteria:
* Body mass index (BMI) of 18.0 to 32.0 kilogram per meter square (kg/m\^2), inclusive
* A total body weight of more than (\>) 50 kg
* Participants must have regular bowel movements (i.e., average of more than or equal to (\>=) 1 and less than or equal to (\
Source: ClinicalTrials.gov (NCT07868926). StuddyBuddy aggregates publicly available trial information.
